Specificity of research antibodies: “trust is good, validation is better”

We are writing you in regard to the article "Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up" by Chen et al., published 16 August 2017 in Human Pathology [1]. The authors used immunohistochemistry to analyze the expression of several signal transduction markers in tissues samples from 672 breast cancer patients and concluded that elevated levels of phosphorylated protein phosphatase 2A (PP2A) catalytic subunit correlate with a shorter 15-year overall survival rate.

http://ift.tt/2CdvWcJ